Request Study Information

After you submit your request, a staff member will contact you.There’s no obligation and our team is here to help you decide on a study that’s best for you.

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular(CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) trial.

Rovia St. Augustine (ECIR Site)

The recently completed dal-GenE study, a clinical trial of over 6,000 patients, evaluated the effects of dalcetrapib in patients with recent ACS and the AA genetic variant. The results of this large study demonstrated that treatment with dalcetrapib did not change the risk of having another cardiovascular event in the majority of patients with recent ACS. However, an analysis was performed which indicated that the COVID-19 pandemic may have impacted the accuracy of this data. When the results collected before the start of the COVID-19 pandemic were evaluated, certain analyses showed that taking dalcetrapib corresponded to a reduction in chance of experiencing a myocardial infarction (heart attack) when compared to those taking placebo (dummy drug). The goal of the present study is to evaluate the effect of dalcetrapib only in patients with the AA genetic variant to confirm these findings of cardiovascular benefit.

Enter Your Information

(All fields are required)

Study Request Form (specific)

Name(Required)

First Name Last Name

Phone Number(Required)

Email Address(Required)

Zip / Postal Code(Required)

Date of Birth(Required)

Gender(Required)

Preferred Location(Required)

Study Of Interest(Required)

Preferred Language(Required)

Are you Hispanic or Latino(Required)

Race(Required)

Select one or more options that best describe you. This information can help ensure that all populations are represented in research.

American Indian or Alaskan Native

Asian

Black or African American

Native Hawaiian or Other Pacific Islander

White or Caucasian

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from ECIR and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at [email protected]. For full details, refer to ECIR’s privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.

CAPTCHA

Headquarters
3550 University Blvd South, Suite #101
Jacksonville, FL 32216

Tel: (904) 854-1354
Fax: (904) 854-1355